Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, REGENXBIO Inc. reported revenue of $170M, up 104.5% year over year. Operating margin was -94.6% and net margin -113.8%, on a free-cash-flow margin of -74.1% with capital expenditure at 1.4% of revenue. Every figure is computed directly from RGNX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $170M | -94.6% | -113.8% |
| FY2024 | $83M | -280.0% | -272.5% |
| FY2023 | $90M | -297.1% | -292.0% |
| FY2022 | $113M | -233.2% | -248.7% |
| FY2021 | $470M | 34.0% | 27.2% |
How does RGNX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.